An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3172-3176

  Liu, Glenn ^a   Kelly, W Kevin ^b   Wilding, George ^a   Leopold, Lance ^c   Brill, Kimberli ^c   Somer, Bradley ^d  

^a UNIVERSITY OF WISCONSIN   (United States)

^b YALE UNIVERSITY MEDICAL CENTER   (United States)

^c Ascenta Therapeutics   (United States)

^d WEST CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

'AT 101'; GOSSYPOL ACETIC ACID; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ABDOMINAL DISTENSION; ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; BONE PAIN; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; GASTROESOPHAGEAL REFLUX; HUMAN; ILEUS; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECOMMENDED DRUG DOSE; SMALL INTESTINE OBSTRUCTION; TREATMENT RESPONSE; WEAKNESS; XEROSTOMIA;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; GOSSYPOL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 65649130832     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2985     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004;92:287-295 (Pubitemid 40128250)
3. Eisenberger M. Chemotherapy for prostate carcinomas. NCI Monogr 1988;7:151-163
4. Kantoff PW, Halabi S, Conaway M, et al. Hydrocodone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-2513
5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764
6. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400.
7. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944
8. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 1998;273:30777-30784
9. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-1255 (Pubitemid 26080965)
10. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:299-333 (Pubitemid 27038278)
11. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512
12. Petrylak DP, Tangen CM, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520
13. Adams R, Geissman TA. Gossypol, a pigment of cottonseed. Chem Rev 1960;60:555-574
14. Meng Y, Tang W, Dai Y, et al. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008;7:2192-2202
15. Van Poznak C, Seidman AD, Reidenberg MM, et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat 2001;66:239-248
16. Jiang J, Sugimoto Y, Liu S, et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor β 1 (TGFβ1) signal transduction pathway. Anticancer Res 2004;24:91-100.
17. Ko CH, Shen SC, Yang LY, Lin CW, Chen YC. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells. Int J Cancer 2007;121:1670-1679 (Pubitemid 47417282)
18. Wolter KG, Wang SJ, Henson BS, et al. (-)-Gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006;8:163-172
19. James DF, Prada CE, Castro JE, Kipps TJ. AT 101, an Inhibitor of Bcl-2 family members is cytotoxic to a heterogeneous group of primary CLL samples and synergistic with rituximab. Blood 2005. ASH Annual Meeting Abstract 7C2BA.
20. Mohammad RM, Wang S, Aboukameel A, et al. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-xL [(0)-gossypol] against diffuse large cell lymphoma. Mol Cancer Ther 2005;4:13-21.
21. Kline MP, Rajkumar SV, Timm MM, et al. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol 2008;36:568-576
22. National Cancer Institute: Cancer Therapy Evaluation Program Common Toxicity Criteria, version 3.0, modified 2006. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf.
23. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;11:3461-3467
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
25. Saleh M, Pitot H, Holmlund J, Maleski J, Forero A. Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers. ASCO Annual Meeting Abstracts, May 2007;3583.
26. Castro JE, Loria OJ, Aguillon RA et al. A phase ii, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. evaluation of two dose regimens. Blood (ASH Annual Meeting Abstracts), Nov 2007;110:3119.
27. Freund H, Hurvitz H, Schiller M. Etiologic and therapeutic aspects of intussusceptions in childhood. Am J Surg 1977;134:272-274 (Pubitemid 8160956)
28. MacVicar G, Greco FA, Reeves J, et al. An open-label, multicenter, phase 1/2 study of AT-101 in combination with docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC) [abstract #209]. EORTC/NCI/AACR Proceedings 2008.
29. Loberg RD, McGregor N, Ying C, Sargent E, Pienta KJ. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration. Neoplasia 2007;9:1030-1037